Vita Life Sciences Ltd
ASX:VLS

Watchlist Manager
Vita Life Sciences Ltd Logo
Vita Life Sciences Ltd
ASX:VLS
Watchlist
Price: 1.915 AUD
Market Cap: 107.3m AUD
Have any thoughts about
Vita Life Sciences Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one VLS stock under the Base Case scenario is 2.07 AUD. Compared to the current market price of 1.915 AUD, Vita Life Sciences Ltd is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VLS Relative Value
Base Case
2.07 AUD
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.4
P/S
P/S
Price to Sales
1.4
vs History
30
vs Industry
59
Median 3Y
1.5
Median 5Y
1.3
Industry
2.5
More Details
11.5
P/E
P/E
Price to Earnings
11.5
vs History
31
vs Industry
32
Median 3Y
12.1
Median 5Y
11.7
Industry
21.4
More Details
9.8
P/OCF
P/OCF
Price to OCF
9.8
vs History
61
vs Industry
37
Median 3Y
13.3
Median 5Y
11.6
Industry
16
More Details
10.3
P/FCFE
P/FCFE
Price to FCFE
10.3
vs History
65
vs Industry
29
Median 3Y
14.7
Median 5Y
12.8
Industry
23.3
More Details
2.2
P/B
P/B
Price to Book Value
2.2
vs History
42
vs Industry
28
Median 3Y
2.6
Median 5Y
2.3
Industry
2.1
More Details
1
EV/S
EV/S
Enterprise Value to Sales
1
vs History
34
vs Industry
64
Median 3Y
1.2
Median 5Y
1
Industry
2.6
More Details
1.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.7
vs History
31
vs Industry
68
Median 3Y
2
Median 5Y
1.8
Industry
5.1
More Details
6.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6.6
vs History
33
vs Industry
38
Median 3Y
7.3
Median 5Y
6.5
Industry
13.7
More Details
6.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
6.6
vs History
33
vs Industry
40
Median 3Y
7.3
Median 5Y
6.5
Industry
16.7
More Details
7.3
EV/OCF
EV/OCF
Enterprise Value to OCF
7.3
vs History
65
vs Industry
41
Median 3Y
10.8
Median 5Y
9.1
Industry
15.1
More Details
7.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
7.7
vs History
63
vs Industry
31
Median 3Y
11.1
Median 5Y
9.6
Industry
18.9
More Details
2.9
EV/IC
EV/IC
Enterprise Value to IC
2.9
vs History
28
vs Industry
22
Median 3Y
3.2
Median 5Y
2.7
Industry
1.9
More Details

Multiples Across Competitors

VLS Competitors Multiples
Vita Life Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Vita Life Sciences Ltd
ASX:VLS
108m AUD 1.4 11.5 6.6 6.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
747.7B USD 18.3 89.3 48 53.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.1 28.9 20.1 22.9
US
Johnson & Johnson
NYSE:JNJ
342.5B USD 3.9 23.3 11.3 14.7
US
Merck & Co Inc
NYSE:MRK
252.8B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
212.8B CHF 3.6 18.5 10.4 12.3
UK
AstraZeneca PLC
LSE:AZN
166.7B GBP 4.2 32 169.6 254.2
CH
Novartis AG
SIX:NOVN
178B CHF 3.9 11.1 9.6 13.4
US
Pfizer Inc
NYSE:PFE
152.2B USD 2.5 35.8 10.6 16
P/E Multiple
Earnings Growth PEG
AU
Vita Life Sciences Ltd
ASX:VLS
Average P/E: 30.1
11.5
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.3
76%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
28.9
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.3
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
18.5
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32
40%
0.8
CH
Novartis AG
SIX:NOVN
11.1
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.8
102%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBITDA: 414.3
6.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
42%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.1
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.3
4%
2.8
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.4
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.6
18%
9.4
CH
Novartis AG
SIX:NOVN
9.6
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBIT: 1 810.9
6.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.6
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
22.9
22%
1
US
Johnson & Johnson
NYSE:JNJ
14.7
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
12.3
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
254.2
32%
7.9
CH
Novartis AG
SIX:NOVN
13.4
17%
0.8
US
Pfizer Inc
NYSE:PFE
16
19%
0.8

See Also

Summary
VLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
VLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VLS stock valuation using valuation multiples.
Wall Street Estimates
VLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 215,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.